An observational study in Neurologic Disorder and Central Nervous System Diseases, sponsored by Imagine Institute. Not yet recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Imagine Institute · Observational
In the context of adult pathology, research into biomarkers in cerebrospinal fluid (CSF) has already identified proteins that are commonly used for the early diagnosis of certain neurodegenerative diseases. However, the lack of data available in the literature on pediatric diseases has limited the use of biomarkers in routine practice in children. Importantly, our group has pioneered the establishment of CSF biomarkers in children (e.g., measurement of interferon alpha in CSF by ultra-sensitive digital ELISA), which will undoubtedly be used in routine clinical practice in the future. In light of these arguments, the establishment of a CSF biobank will have major clinical implications, given the rarity of the diseases treated and the number of patients followed.
386 studies on the registry are indexed under Central Nervous System Diseases; 104 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 139 across 73 observational studies indexed under Central Nervous System Diseases.
Browse Central Nervous System Diseases studies →Imagine Institute is the lead sponsor of 31 studies on the registry; 15 are open to participants now.
Compared within Central Nervous System Diseases, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nervous System Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients with a neurological condition diagnosed by a physician requiring cerebrospinal fluid (CSF) collection as a part of their health care
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with a neurological condition diagnosed by a physician requiring cerebrospinal fluid (CSF) collection, through:
Exclusion Criteria:
1. Objection by the patient and/or the legal guardian, if the patient is a minor, to participation in the study.
Patients with a neurological condition diagnosed by a physician and requiring CSF sampling as part of their routine care
Longitudinal evolution of protein markers in CSF from patients with central nervous system involvement
Time frame: 2021 - 2035
Longitudinal changes in inflammatory protein levels in the CSF of patients with post-hemorrhagic hydrocephalus
Time frame: 2021 - 2035
Proteomic characterization of several neuroinflammatory diseases
Time frame: 2021 - 2035
Identification of biomarkers of severity in children with traumatic brain injury
Time frame: 2021 - 2035
Comparison of CSF biomarkers with data generated in serum (when available)
Proteomic analysis by comparing LCS biomarker results with data generated in serum, in order to discover new biomarkers relevant to the pathology under study.
Time frame: 2021 - 2035
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Nervous System Diseases →
Imagine Institute